Severe hepatic impairment. Assess glycemic status prior to initiation of therapy. Weekly self-monitoring of blood glucose for the 1st 2 or 3 mth & periodically thereafter. Discontinue if uncontrolled hyperglycemia persists. Cushing's disease patients w/ poor glycemic control. Monitor for signs & symptoms associated w/ hypocorticolism & liver function. History of clinically significant bradycardia or acute MI, high-grade heart block, CHF (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation. Patients w/ significant risk of developing QT prolongation. Correct hypokalemia or hypomagnesemia prior to & monitored periodically during therapy. Gallbladder ultrasonic exam prior to & 6- to 12-mth intervals during therapy. Monitor pituitary function prior to initiation & periodically during therapy. Elderly >65 yr. Childn <18 yr. Pregnancy & lactation.